Filing Flows

Filing Flows › Vanda Pharmaceuticals (VNDA) › Next earnings date

Vanda Pharmaceuticals (VNDA) earnings

Vanda Pharmaceuticals (VNDA) last reported on Oct 28, 2026: revenue $69.8M for the third quarter 2026. The next date is not set yet. It beat the EPS estimate in 40% of the quarters on record.

Beat rate40%

The last report

Vanda Pharmaceuticals reported revenue of $69.8M for the third quarter 2026 (+24% Y/Y), net loss $22.6M: Fanapt® $38.8M, HETLIOZ® net product sales $21.7M, PONVORY® net product sales $7.7M, NEREUSTM $1.6M. How it makes money → · Every quarter →

Vanda Pharmaceuticals: EPS against the estimate, last 5 reportsVanda Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.45−$0.38Oct 25−$1.32−$2.39Feb 26−$0.69−$0.82May 26−$0.59−$1.04Aug 26−$0.68−$0.37Oct 26
Latest (Oct 26): Estimate −$0.68, Reported −$0.37.

Vanda Pharmaceuticals' latest quarter

Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.

Questions

When does VNDA report earnings?

The next date is not set yet.

Does Vanda Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.